AI drug discovery company

Aureka Bio

Data as of Oct 17, 2026.

Company facts

Founded

2023

ReportedSource for founded (opens in new tab)
Headquarters

United States (Laguna Hills, CA)

ConfirmedSource for headquarters (opens in new tab)
Total funding

$200M

ConfirmedSource for total funding (opens in new tab)

Latest funding round

Round: Series B
Date: Aug 11, 2026
Amount: $100M
Lead investor: Granite Asia (first tranche); a strategic investor led the next tranche

ConfirmedSource for the latest round (opens in new tab)

Big tech ties

Not counted as pharma partners.

NVIDIA

Proof-of-concept testing of BioNeMo Inference Runtime, Sep 11, 2026

ConfirmedSource for NVIDIA (opens in new tab)

Recent news

Sep 17, 2026

$100M Series B, AI drug discovery

ReportedSource (opens in new tab)
Sep 11, 2026

Reports proof-of-concept testing of NVIDIA's BioNeMo Inference Runtime with its AuraIDE

ConfirmedSource (opens in new tab)
Aug 11, 2026

Raised $100M Series B

ConfirmedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.